Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

@article{Maubec2011PhaseIS,
  title={Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.},
  author={Eve Maubec and P. Petrow and Isabelle Scheer-Senyarich and Pierre Duvillard and Ludovic Lacroix and Julien Gelly and Agnes Certain and Xavier Duval and B{\'e}atrice Crickx and Val{\'e}rie Buffard and Nicole Basset-Seguin and Pierre Saez and Anne-B{\'e}n{\'e}dicte Duval-Modeste and Henri Adamski and Sandrine Mansard and F. Grange and Anne Dompmartin and Sandrine J. Faivre and France Mentr{\'e} and M‐F. Avril},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 25},
  pages={
          3419-26
        }
}
  • E. MaubecP. Petrow M. Avril
  • Published 1 September 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS). [] Key MethodPATIENTS AND METHODS Thirty-six patients received cetuximab (initial dose of 400 mg/m(2) followed by subsequent weekly doses of 250 mg/m(2)) for at least 6 weeks with a 48-week follow-up.

Figures and Tables from this paper

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

SCT200 monotherapy as the second- or further-line treatment for advanced ESCC showed favorable efficacy, with an acceptable safety profile, and TP53 mutation abundance might serve as a potential predictive biomarker.

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.

Single-agent panitumumab is safe and effective in the management of patients with advanced CSCC even in a previously extensively pre-treated cohort.

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

  • J. GrobR. Gonzalez B. Hughes
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2020
Pembrolizumab demonstrated effective antitumor activity; clinically meaningful, durable responses; and acceptable safety in primarily elderly patients with R/M cSCC, supporting its use in clinical practice.

Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients

Disease control is usually rapidly obtained with cetuximab alone or in combination with conventional chemotherapy, although with a minority of partial responses and no complete response, however, this control is of short duration in most cases.

Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy

The case of a 60-year-old man with unresectable cutaneous squamous cell carcinoma of the sternal area, which was not amenable to radiation therapy, is presented and combination therapy with cetuximab and nivolumab is initiated.

Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Swiss Case Series

This study underlines the current evidence that SCCS can be successfully treated with cetuximab and achieves an overall DCR of 67% at 4-8 weeks of treatment.

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

  • G. KonidarisE. Paul S. Cope
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2021
...

References

SHOWING 1-10 OF 46 REFERENCES

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  • J. VermorkenJ. Trigo J. Baselga
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
Single-agent cetuximab was active and generally well tolerated in the treatment of recurrent and/or metastatic SCCHN that progressed on platinum therapy and response was comparable to that seen with cetUXimab plus platinum combination regimens in the same setting.

Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin.

  • B. GlissonE. Kim S. Lippman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Gefitinib is well tolerated and has modest activity in advanced skin SCC, and survival is ongoing as several patients are still receiving treatment.

Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.

  • D. ShinB. Glisson S. Lippman
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
Combined 13cRA, IFNalpha, and cisplatin was clinically active in extensive locally advanced disease and each agent had independent, non-cross-resistant biologic effects in vitro, which may account for the combination's clinical activity.

Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer

These studies confirm previous reports that tumor EGFR expression levels are not associated with efficacy with an anti- EGFR antibody and that anti-EGFR antibody therapy should be limited to those patients whose tumors express wild-type KRAS.

Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies

Physicians and patients should view rash development as a positive event indicative of greater likelihood of clinical benefit and further studies are required to identify patients most likely to develop rash and to determine if dose escalation to induce rash can improve efficacy.

Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5‐fluorouracil, and bleomycin

The results show that this chemotherapy combination could play a role in reducing the tumor mass and in facilitating definitive treatment to obtain better functional and cosmetic results in advanced SCC of the skin.

Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.

The encouraging responses justify the prospective study of cetuximab in SCCS, and the drug was well tolerated, with the exception of acneiform rash requiring dose reduction in 1 patient.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetUXimab.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

KRAS WT status is associated to survival benefit in CTX treated mCRC, even more pronounced in those patients with early radiological response, and these characteristics may be exploited for response prediction.